Advertisement

Hematologic Cancer Survivorship Management: Transplantation

  • Karen Stolar
  • Amin Alousi
  • Joyce Neumann
  • Richard Champlin
Chapter
Part of the MD Anderson Cancer Care Series book series (MDCCS)

Abstract

This chapter will review the late effects of treatment impacting hematopoietic stem cell transplantation (HSCT) survivors. In general, HSCT patients receive high doses of chemotherapy with or without radiation therapy to eradicate their malignancy, together with an infusion of their own (autologous) or another person’s (allogeneic) stem cells to restore hematopoiesis (the blood and immune system). Allogeneic cells may be from bone marrow, peripheral blood, or umbilical cord blood obtained from a related or unrelated donor. Patients experience the toxic effects of the cytotoxic treatment and are at high risk for infections owing to posttransplant immune deficiency. Late effects for HSCT survivors are commonly compounded by the toxic effects of their previous cancer treatment. This chapter will cover physiologic and psychological aspects of survivorship for HSCT patients, as well as graft-versus-host disease, a common and frequently chronic condition that occurs after allogeneic HSCT.

Keywords

Hematopoietic Stem Cell Transplantation Total Body Irradiation Acute GVHD Allogeneic Hematopoietic Stem Cell Transplantation Chronic GVHD 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Readings

  1. Al-Hazzouri A, Cao Q, Burns LJ, et al. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008;14:658–663.PubMedCrossRefGoogle Scholar
  2. Bjorklund A, Aschan J, Labopin M, et al. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant 2007;40:1055–1062.PubMedCrossRefGoogle Scholar
  3. den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476–1480.CrossRefGoogle Scholar
  4. Dobr T, Passweg J, Weber C, et al. Oral health risks associated with HLA-types of patients undergoing hematopoietic stem cell transplantation. Eur J Haematol 2007;78:495–499.PubMedCrossRefGoogle Scholar
  5. Dudek AZ, Mahaseth H. Hematopoietic stem cell transplant-related airflow obstruction. Curr Opin Oncol 2006;18:115–119.PubMedCrossRefGoogle Scholar
  6. Fadol A, Mendoza T, Gning I, et al. Psychometric testing of the MDASI-HF: a symptom assessment instrument for patients with cancer and concurrent heart failure. J Card Fail 2008;14:497–507.PubMedCrossRefGoogle Scholar
  7. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–956.PubMedCrossRefGoogle Scholar
  8. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923–1930.PubMedCrossRefGoogle Scholar
  9. Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006;108:2867–2873.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987;67:397–406.PubMedCrossRefGoogle Scholar
  11. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281–285.PubMedCrossRefGoogle Scholar
  12. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005;13:322–327.PubMedGoogle Scholar
  13. Hahn T, McCarthy PL, Jr., Zhang MJ, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008;26:5728–5734.PubMedCrossRefPubMedCentralGoogle Scholar
  14. Hingorani S. Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant. Pediatr Nephrol 2008;23:879–888.PubMedCrossRefPubMedCentralGoogle Scholar
  15. Jacobs SR, Small BJ, Booth-Jones M, et al. Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. Cancer 2007;110:1560–1567.PubMedCrossRefGoogle Scholar
  16. Kersting S, Koomans HA, Hene RJ, et al. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant 2007;39:359–365.PubMedCrossRefGoogle Scholar
  17. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008:134–141.Google Scholar
  18. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002;100:406–414.PubMedCrossRefGoogle Scholar
  19. Lee SJ, Loberiza FR, Antin JH, et al. Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant 2005;35:77–83.PubMedCrossRefGoogle Scholar
  20. Leite SC, de Castro RS, Alves M, et al. Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Transplant 2006;38:223–227.PubMedCrossRefGoogle Scholar
  21. Loberiza FR, Jr., Rizzo JD, Bredeson CN, et al. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol 2002;20:2118–2126.PubMedCrossRefGoogle Scholar
  22. Loren AW, Chow E, Jacobsohn DA, et al. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2011;17:157–166.PubMedCrossRefPubMedCentralGoogle Scholar
  23. Majhail NS. Old and new cancers after hematopoietic-cell transplantation. Hematology Am Soc Hematol Educ Program 2008;2008:142–149.CrossRefGoogle Scholar
  24. Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011;117:316–322.PubMedCrossRefPubMedCentralGoogle Scholar
  25. Mohty M, Apperley JF. Long-term physiological side effects after allogeneic bone marrow transplantation. Hematology Am Soc Hematol Educ Program 2011;2010:229–236.CrossRefGoogle Scholar
  26. Molldrem JJ, Komanduri K, Wieder E. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol 2002;9:503–508.PubMedCrossRefGoogle Scholar
  27. Mosher CE, Redd WH, Rini CM, et al. Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature. Psychooncology 2009;18:113–127.PubMedCrossRefPubMedCentralGoogle Scholar
  28. Pandya CM, Soubani AO. Bronchiolitis obliterans following hematopoietic stem cell transplantation: a clinical update. Clin Transplant 2010;24:291–306.PubMedCrossRefGoogle Scholar
  29. Patriarca F, Poletti V, Costabel U, et al. Clinical presentation, outcome and risk factors of late-onset non-infectious pulmonary complications after allogeneic stem cell transplantation. Curr Stem Cell Res Ther 2009;4:161–167.PubMedCrossRefGoogle Scholar
  30. Poppelreuter M, Weis J, Mumm A, et al. Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;41:79–90.PubMedCrossRefGoogle Scholar
  31. Prasad VK, Kernan NA, Heller G, et al. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood 1999;93:399–409.PubMedGoogle Scholar
  32. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001;98:1695–1700.PubMedCrossRefGoogle Scholar
  33. Remberger M, Kumlien G, Aschan J, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:674–682.PubMedCrossRefGoogle Scholar
  34. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009;113:1175–1183.PubMedCrossRefPubMedCentralGoogle Scholar
  35. Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant 2007;13:1304–1312.Google Scholar
  36. Roziakova L, Mladosievicova B. Endocrine late effects after hematopoietic stem cell transplantation. Oncol Res 2010;18:607–615.PubMedCrossRefGoogle Scholar
  37. Schulmeister L, Quiett K, Mayer K. Quality of life, quality of care, and patient satisfaction: perceptions of patients undergoing outpatient autologous stem cell transplantation. Oncol Nurs Forum 2005;32:57–67.PubMedCrossRefGoogle Scholar
  38. Schwartz JL, Kopecky KJ, Mathes RW, et al. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res 2009;171:155–163.PubMedCrossRefPubMedCentralGoogle Scholar
  39. Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003;101:3373–3385.PubMedCrossRefGoogle Scholar
  40. Socie G, Tichelli A. Long-term care after stem-cell transplantation. Hematol J 2004;5 Suppl 3:S39–S43.PubMedCrossRefGoogle Scholar
  41. Syrjala KL, Kurland BF, Abrams JR, et al. Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood 2008;111:989–996.PubMedCrossRefPubMedCentralGoogle Scholar
  42. Syrjala KL, Langer SL, Abrams JR, et al. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA 2004;291:2335–2343.PubMedCrossRefGoogle Scholar
  43. Syrjala KL, Langer SL, Abrams JR, et al. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 2005;23:6596–6606.PubMedCrossRefGoogle Scholar
  44. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007;110:3463–3471.PubMedCrossRefGoogle Scholar
  45. Tichelli A, Rovo A, Gratwohl A. Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices. Hematology Am Soc Hematol Educ Program 2008;2008:125–133.CrossRefGoogle Scholar
  46. Tichelli A, Rovo A, Passweg J, et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol 2009;2:583–601.PubMedCrossRefGoogle Scholar
  47. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant 2009;44:453–455.PubMedCrossRefGoogle Scholar
  48. Witherspoon RP, Deeg HJ, Lum LG, et al. Immunologic recovery in human marrow graft recipients given cyclosporine or methotrexate for the prevention of graft-versus-host disease. Transplantation 1984;37:456–461.PubMedCrossRefGoogle Scholar
  49. Worel N, Biener D, Kalhs P, et al. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant 2002;30:619–626.PubMedCrossRefGoogle Scholar

Copyright information

© The University of Texas M. D. Anderson Cancer Center 2015

Authors and Affiliations

  • Karen Stolar
    • 1
  • Amin Alousi
    • 1
  • Joyce Neumann
    • 1
  • Richard Champlin
    • 1
  1. 1.Department of Stem Cell Transplantation and Cellular TherapyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations